This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dunn, J. Search for Related Content PubMed Articles by Dunn, J. Social Bookmarking                         What's this?

Doxorubicin-Induced Cardiomyopathy

13 Pine Hollow Dr, Londonderry, NH 03053

Doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH) is one of the most effective chemotherapeutic agents used in the management of pediatric neoplastic disorders during the past 20 years. However, its use has been limited by well-characterized, dose-related cardiac toxicity. Recently, cardiac dysfunction has been noted in pediatric patients who had received doxorubicin years before. This article summarizes current information regarding the pathophysiology and risk factors associated with cardiotoxicity and reviews detection methods and treatments of this condition.

Journal of Pediatric Oncology Nursing, Vol. 11, No. 4, 152-160 (1994)
DOI: 10.1177/104345429401100406


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. A. Hollinger and S. N. Giri In Vitro Uptake and Subcellular Distribution of the Cardiotoxin [3H]Adriamycin in Mouse Ventricle Slices International Journal of Toxicology, October 1, 1996; 15(5): 408 - 415. [Abstract] [PDF]